373 related articles for article (PubMed ID: 23864273)
1. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis.
Abrahamsson SV; Angelini DF; Dubinsky AN; Morel E; Oh U; Jones JL; Carassiti D; Reynolds R; Salvetti M; Calabresi PA; Coles AJ; Battistini L; Martin R; Burt RK; Muraro PA
Brain; 2013 Sep; 136(Pt 9):2888-903. PubMed ID: 23864273
[TBL] [Abstract][Full Text] [Related]
2. Reconstitution of immune cell populations in multiple sclerosis patients after autologous stem cell transplantation.
Karnell FG; Lin D; Motley S; Duhen T; Lim N; Campbell DJ; Turka LA; Maecker HT; Harris KM
Clin Exp Immunol; 2017 Sep; 189(3):268-278. PubMed ID: 28498568
[TBL] [Abstract][Full Text] [Related]
3. Autologous haematopoietic stem cell transplantation restores the suppressive capacity of regulatory B cells in systemic sclerosis patients.
Lima-Júnior JR; Arruda LCM; Gonçalves MS; Dias JBE; Moraes DA; Covas DT; Simões BP; Oliveira MC; Malmegrim KCR
Rheumatology (Oxford); 2021 Dec; 60(12):5538-5548. PubMed ID: 33724344
[TBL] [Abstract][Full Text] [Related]
4. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.
Burt RK; Loh Y; Cohen B; Stefoski D; Balabanov R; Katsamakis G; Oyama Y; Russell EJ; Stern J; Muraro P; Rose J; Testori A; Bucha J; Jovanovic B; Milanetti F; Storek J; Voltarelli JC; Burns WH
Lancet Neurol; 2009 Mar; 8(3):244-53. PubMed ID: 19186105
[TBL] [Abstract][Full Text] [Related]
5. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation.
Darlington PJ; Touil T; Doucet JS; Gaucher D; Zeidan J; Gauchat D; Corsini R; Kim HJ; Duddy M; Jalili F; Arbour N; Kebir H; Chen J; Arnold DL; Bowman M; Antel J; Prat A; Freedman MS; Atkins H; Sekaly R; Cheynier R; Bar-Or A;
Ann Neurol; 2013 Mar; 73(3):341-54. PubMed ID: 23463494
[TBL] [Abstract][Full Text] [Related]
6. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
Moore JJ; Massey JC; Ford CD; Khoo ML; Zaunders JJ; Hendrawan K; Barnett Y; Barnett MH; Kyle KA; Zivadinov R; Ma KC; Milliken ST; Sutton IJ; Ma DDF
J Neurol Neurosurg Psychiatry; 2019 May; 90(5):514-521. PubMed ID: 30538138
[TBL] [Abstract][Full Text] [Related]
7. Sustained immunotolerance in multiple sclerosis after stem cell transplant.
Visweswaran M; Hendrawan K; Massey JC; Khoo ML; Ford CD; Zaunders JJ; Withers B; Sutton IJ; Ma DDF; Moore JJ
Ann Clin Transl Neurol; 2022 Feb; 9(2):206-220. PubMed ID: 35106961
[TBL] [Abstract][Full Text] [Related]
8. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation.
Burt RK; Traynor AE; Pope R; Schroeder J; Cohen B; Karlin KH; Lobeck L; Goolsby C; Rowlings P; Davis FA; Stefoski D; Terry C; Keever-Taylor C; Rosen S; Vesole D; Fishman M; Brush M; Mujias S; Villa M; Burns WH
Blood; 1998 Nov; 92(10):3505-14. PubMed ID: 9808541
[TBL] [Abstract][Full Text] [Related]
9. CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: a post hoc analysis of a phase I/II clinical trial conducted in Japan.
Ayano M; Tsukamoto H; Mitoma H; Kimoto Y; Akahoshi M; Arinobu Y; Miyamoto T; Horiuchi T; Niiro H; Nagafuji K; Harada M; Akashi K
Arthritis Res Ther; 2019 Jan; 21(1):30. PubMed ID: 30670057
[TBL] [Abstract][Full Text] [Related]
10. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study.
Farge D; Marolleau JP; Zohar S; Marjanovic Z; Cabane J; Mounier N; Hachulla E; Philippe P; Sibilia J; Rabian C; Chevret S; Gluckman E;
Br J Haematol; 2002 Dec; 119(3):726-39. PubMed ID: 12437652
[TBL] [Abstract][Full Text] [Related]
11. Natalizumab in aggressive multiple sclerosis after haematopoietic stem cell transplantation.
Capobianco M; Motuzova Y; Frau J; Cocco E; Mamusa E; Marrosu MG; Bertolotto A
Neurol Sci; 2012 Aug; 33(4):863-7. PubMed ID: 22116203
[TBL] [Abstract][Full Text] [Related]
12. Analysis of immune reconstitution after autologous CD34+ stem/progenitor cell transplantation for systemic sclerosis: predominant reconstitution of Th1 CD4+ T cells.
Tsukamoto H; Nagafuji K; Horiuchi T; Mitoma H; Niiro H; Arinobu Y; Inoue Y; To K; Miyamoto T; Iwasaki H; Teshima T; Harada M; Akashi K
Rheumatology (Oxford); 2011 May; 50(5):944-52. PubMed ID: 21172925
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis.
Sun W; Popat U; Hutton G; Zang YC; Krance R; Carrum G; Land GA; Heslop H; Brenner M; Zhang JZ
Brain; 2004 May; 127(Pt 5):996-1008. PubMed ID: 14985264
[TBL] [Abstract][Full Text] [Related]
14. The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.
Willison AG; Ruck T; Lenz G; Hartung HP; Meuth SG
J Neurol; 2022 Jul; 269(7):3937-3958. PubMed ID: 35399125
[TBL] [Abstract][Full Text] [Related]
15. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
Steingrimsdottir H; Gruber A; Björkholm M; Svensson A; Hansson M
Haematologica; 2000 Aug; 85(8):832-8. PubMed ID: 10942930
[TBL] [Abstract][Full Text] [Related]
16. Immunological correlates of favorable long-term clinical outcome in multiple sclerosis patients after autologous hematopoietic stem cell transplantation.
Arruda LCM; de Azevedo JTC; de Oliveira GLV; Scortegagna GT; Rodrigues ES; Palma PVB; Brum DG; Guerreiro CT; Marques VD; Barreira AA; Covas DT; Simões BP; Voltarelli JC; Oliveira MC; Malmegrim KCR
Clin Immunol; 2016 Aug; 169():47-57. PubMed ID: 27318116
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory effects of unselected haematopoietic stem cells autotransplantation in refractory Crohn's disease.
Clerici M; Cassinotti A; Onida F; Trabattoni D; Annaloro C; Della Volpe A; Rainone V; Lissoni F; Duca P; Sampietro G; Fociani P; Vago G; Foschi D; Ardizzone S; Deliliers GL; Porro GB
Dig Liver Dis; 2011 Dec; 43(12):946-52. PubMed ID: 21907652
[TBL] [Abstract][Full Text] [Related]
18. Defective expression of apoptosis-related molecules in multiple sclerosis patients is normalized early after autologous haematopoietic stem cell transplantation.
de Oliveira GL; Ferreira AF; Gasparotto EP; Kashima S; Covas DT; Guerreiro CT; Brum DG; Barreira AA; Voltarelli JC; Simões BP; Oliveira MC; de Castro FA; Malmegrim KC
Clin Exp Immunol; 2017 Mar; 187(3):383-398. PubMed ID: 28008595
[TBL] [Abstract][Full Text] [Related]
19. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.
Atkins HL; Bowman M; Allan D; Anstee G; Arnold DL; Bar-Or A; Bence-Bruckler I; Birch P; Bredeson C; Chen J; Fergusson D; Halpenny M; Hamelin L; Huebsch L; Hutton B; Laneuville P; Lapierre Y; Lee H; Martin L; McDiarmid S; O'Connor P; Ramsay T; Sabloff M; Walker L; Freedman MS
Lancet; 2016 Aug; 388(10044):576-85. PubMed ID: 27291994
[TBL] [Abstract][Full Text] [Related]
20. Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis.
Samijn JP; te Boekhorst PA; Mondria T; van Doorn PA; Flach HZ; van der Meché FG; Cornelissen J; Hop WC; Löwenberg B; Hintzen RQ
J Neurol Neurosurg Psychiatry; 2006 Jan; 77(1):46-50. PubMed ID: 16361591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
